2 results match your criteria: "ASL ROMA 1 Santo Spirito Hospital of Rome Rome Italy.[Affiliation]"
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
January 2024
Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari.
Article Synopsis
- - In the ELOQUENT-3 trial, the combination therapy of elotuzumab, pomalidomide, and dexamethasone (EloPd) showed better results for treating relapsed/refractory multiple myeloma (RRMM) compared to pomalidomide and dexamethasone alone, leading to its approval for specific patients.
- - A real-world study of 200 RRMM cases in Italy confirmed similar effectiveness and manageable side effects for EloPd, with a 55.4% overall response rate and a median progression-free survival of 7 months, though these were lower than results from the ELOQUENT-3 trial.
- - Factors like the number of previous
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The association between CLL and glomerular disease (GD) is rare. The most frequent GD associated with CLL is membranoproliferative membranous glomerulonephritis (GN) (MPGN) (45%) types I and II, followed by membranous glomerulonephritis, with the same reports of immunotactoid glomerulopathy (ITG).
View Article and Find Full Text PDF